Veer Bhavnagri - 14 Mar 2023 Form 4 Insider Report for Allogene Therapeutics, Inc. (ALLO)

Reporting relationship: General Counsel
Issuer ticker: ALLO
Reported as of: 14 Mar 2023
Net transaction value: -$133,971
SEC form: 4
Accepted by SEC: 16 Mar 2023, 16:46:11 UTC
Prior SEC filing: 14 Feb 2023
Source filing: View source filing
Reporting owner signature: /s/Veer Bhavnagri

Key filing fact

Veer Bhavnagri filed Form 4 for Allogene Therapeutics, Inc. (ALLO) on 16 Mar 2023.

Key facts

This page summarizes Veer Bhavnagri's Form 4 filing for Allogene Therapeutics, Inc. (ALLO).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 16 Mar 2023, 16:46.

Change

Previous filing in this sequence was filed on 14 Feb 2023.
Current net transaction value: -$133,971.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ALLO transaction

Common Stock

Tax liability

Transaction value: $133,971
Shares: -23,628
Change %: -4.1%
Price: $5.67
Shares after: 556,049
Date: 14 Mar 2023
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

Footnote F2

Includes 2,000 shares of the Issuer's common stock acquired by the reporting person on March 15, 2023 pursuant to an employee stock purchase program.